Bonino F, Ponzetto A, Veglio V, Bosio G, Zaffino M C, Rizzetto M
Ric Clin Lab. 1977 Oct-Dec;7(4):365-72. doi: 10.1007/BF02886649.
Serological screening for HBeAg and anti-HBe, combined with the immunohistochemical localization of the hepatitis B core and surface antigen in 110 HBsAg carriers, established different immunological profiles indicative of the liver status and prognostic of the future absence or progression of the disease. Intrahepatic HBcAg and serum HBeAg appeared the most sensitive indexes of chronic and progressive liver disease, anti-HBe and large amounts of cytoplasmic HBsAg suggest, instead, the asymptomatic carrier state without liver damage. Only the nuclear localization of HBcAg in immunohistochemical studies was a reliable prognostic indicator of transition to chronicity; absence or presence of serum HBeAg was of no help in predicitng the outcome of acute HBsAg hepatitis.
对110例乙肝表面抗原(HBsAg)携带者进行乙肝e抗原(HBeAg)和乙肝e抗体(抗-HBe)的血清学筛查,并结合乙肝核心抗原和表面抗原的免疫组化定位,确立了不同的免疫模式,这些模式可指示肝脏状态以及疾病未来是否会消失或进展的预后情况。肝内乙肝核心抗原(HBcAg)和血清HBeAg似乎是慢性和进行性肝病最敏感的指标,而抗-HBe和大量细胞质乙肝表面抗原(HBsAg)则提示无症状携带者状态且无肝损伤。在免疫组化研究中,只有HBcAg的核定位是向慢性转变的可靠预后指标;血清HBeAg的有无对预测急性HBsAg肝炎的转归并无帮助。